drugset / Trial / NCT02633046

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

NCT02633046

Phase 4 Completed 63 enrolled Mallinckrodt
NaSingle-groupOpen-labelTreatment

Summary

Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get into the kidney. FSGS is a serious condition that can lead to kidney failure. The only treatment for kidney failure is dialysis or kidney transplant. Proteinuria means too much protein came through the kidneys into the urine. If the doctor cannot figure out what is causing the problem, it is primary (idiopathic) FSGS. This kind of FSGS is very hard to treat. This study will test Acthar in patients with this condition who have not responded to other treatments. It primarily investigates how well the therapy is tolerated by the patients and how well they respond to this treatment.

Timeline

Start
2016-10-10
Primary completion
2020-08-27
Completion
2020-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 80 iu Subcutaneous